Majority shareholder approves reverse stock split up to 1-for-10 for Sunshine Biopharma

Sunshine Biopharma Inc.

Dr. Steve N. Slilaty, holding ~96% voting power, approved by written consent a reverse split of common stock up to 1-for-10.
Board has discretion on whether to effect the reverse split and the exact ratio (whole number up to 1-for-10).
Shareholder consent will be effective 20 days after mailing definitive information statement to stockholders.
Dr. Slilaty is CEO and controls approximately 96% of total voting power.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.